Table 2.
Pt | Age - gender – primary disease | TST (mm) | Treatment at QTF-G performance | QTF-G IFN-γ concentrations (TB antigens-nil) | LTBI chemoprophylaxis | Maximum ALT/AST (IU/L) | Time on anti-TNFα drugs (before/after LTBI chemoprophylaxis) |
---|---|---|---|---|---|---|---|
1 | 11y6m – female- polyarticular JIA, negative RF |
0 | ETN + MTX | 0.55 IU/mL | H for 9 months | 30/37 | 22 (1/24) months |
2 | 10y7m – female - oligoarticular JIA |
0 | ETN | 0.37 IU/mL | HR for 3 months | 31/38 | 29 (14/25) months |
3 | 8y5m – female - oligoarticular JIA |
15 | NSAIDs | 4.78 IU/mL | HR for 3 months | 25/24 | 12 (0/29) months |
ALT alanine aminotransferase, AST aspartate aminotransferase, H isoniazid, IFN-γ interferon-gamma, MTX methotrexate, NSAIDs non-steroidal anti-inflammatory drugs, Pt patient, R rifampicin, RF rheumatoid factor